Imbruvica vs Keytruda Analysis Shows Why Merck (NYSE:MRK) Stock Is Worth Buying Now

- September 7, 2017

Imbruvica and Keytruda are two of the biggest breakthrough cancer drugs in history. Both are expected to have broad usage with Imbruvica for various types of blood cancer and Keytruda as the superior drug in a class known as anti PD-1 and PD-L1. Merck & Co (NYSE:MRK) is the manufacturer of Keytruda whereas Johnson & Johnson (NYSE:JNJ) and AbbVie Inc (NYSE:ABBV) share in Imbruvica’s costs and revenue.

Back in 2015, AbbVie purchased Imbruvica with its acquisition of Pharmacyclics for $21 billion. That massive purchase price entitled AbbVie (NYSE:ABBV) to 50% of Imbruvica’s revenue, while only being responsible for 40% of the costs. Johnson & Johnson (NYSE:JNJ) maintained its remaining share.

Clearly, the massive purchase price for just half of a drug implies both incredibly high expectations and an equally massive valuation for the drug as a whole. This realization is what makes Merck & Co (NYSE:MRK) look so attractive.

I created the above chart while playing around on the HADE Platform, accessing and visualizing various data points. I started comparing and contrasting the performance of drugs. I noticed that Keytruda and Imbruvica launched around the same time, and that Imbruvica had higher revenues in the first quarter of last year. As of Q2, Keytruda’s sales were nearly twice that of Imbruvica, from J&J.

Furthermore, check out the difference in growth rate below! That’s 52% growth for Imbruvica vs 180% growth for Keytruda!

With that said, Imbruvica is still one hell of a drug, one with mega blockbuster potential. However, if this data illustrates anything it is that the potential for Keytruda is simply ridiculous. This brings up a very important question, one to ask ourselves: If half of Imbruvica is worth $21 billion, then what is all of Keytruda worth? I think the answer could be mind boggling over time, for Merck stock owners.

This entry was posted in HADE Platform, Healthcare & Biotech, Members, Mergers & Acquisitions Bookmark the permalink.
RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.







Join the 100s Who Beat the Market with a BNL Membership

See What Current Members Are Saying

My Complete Access BNL Membership Includes

  • No contract. Guaranteed results. Cancel anytime.
  • Unrivaled Performance. The BNL Portfolio has outperformed the S&P 500 by 150% since October 1, 2015
  • Access. You know what goes in the BNL Portfolio, David’s Dividend Portfolio, and Eddy’s Options.
  • Alerts. You know when a trade is made in all three managed portfolios with application, text, and email alerts
  • Transparency. Verifiable trade records for the BNL Portfolio, David’s Dividends, & Eddy’s Options
  • Research. We have coverage on more than 50 companies
  • Results. Our 10 highest rated stocks outperformed the market by 134% last year
  • Live Chat. Join 100s of other members in an exclusive Members Only section with Chat
  • Growth. We are the fastest growing financial research platform in our industry.
  • Build My Portfolio. You give us your goals, we help you get there
  • Premium Content. Unlock hidden sections in each article. You also get Value of the Month selections and BNL Research Reports.
  • Community. We have professionals and beginners; retirees and college students; the 99% & 1%, but here, we are all equal.


Like what you see? Sign up for our newsletter and get the latest stock picks straight to your email!

%d bloggers like this: